[go: up one dir, main page]

EA200901500A1 - Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека - Google Patents

Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека

Info

Publication number
EA200901500A1
EA200901500A1 EA200901500A EA200901500A EA200901500A1 EA 200901500 A1 EA200901500 A1 EA 200901500A1 EA 200901500 A EA200901500 A EA 200901500A EA 200901500 A EA200901500 A EA 200901500A EA 200901500 A1 EA200901500 A1 EA 200901500A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
granulocitar
neutralizers
human factor
stimulating human
Prior art date
Application number
EA200901500A
Other languages
English (en)
Other versions
EA017420B1 (ru
EA017420B9 (ru
Inventor
Тобиас РАУМ
Хепп (урожденная Хенкель), Юлия
Эва Визер
Петч (урожденная Миттельштрасс), Зилке
Стивен Цеман
Андреас Вульф
Сандра Брукмайер
Original Assignee
Микромет Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Микромет Аг filed Critical Микромет Аг
Publication of EA200901500A1 publication Critical patent/EA200901500A1/ru
Publication of EA017420B1 publication Critical patent/EA017420B1/ru
Publication of EA017420B9 publication Critical patent/EA017420B9/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)

Abstract

Настоящее изобретение относится к человеческому моноклональному антителу или его фрагменту, которые специфически связываются с GM-CSF приматов и нейтрализуют его.
EA200901500A 2005-04-18 2006-04-18 Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека EA017420B9 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05008410 2005-04-18

Publications (3)

Publication Number Publication Date
EA200901500A1 true EA200901500A1 (ru) 2010-10-29
EA017420B1 EA017420B1 (ru) 2012-12-28
EA017420B9 EA017420B9 (ru) 2013-03-29

Family

ID=37115507

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200901500A EA017420B9 (ru) 2005-04-18 2006-04-18 Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека
EA200702008A EA013162B1 (ru) 2005-04-18 2006-04-18 Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200702008A EA013162B1 (ru) 2005-04-18 2006-04-18 Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека

Country Status (28)

Country Link
US (3) US8017748B2 (ru)
EP (2) EP2468774A3 (ru)
JP (1) JP5085533B2 (ru)
KR (2) KR20150091193A (ru)
CN (2) CN101184777B (ru)
AU (1) AU2006237159B2 (ru)
BR (1) BRPI0608281B8 (ru)
CA (1) CA2605402C (ru)
CY (1) CY1116632T1 (ru)
DK (1) DK1874819T3 (ru)
EA (2) EA017420B9 (ru)
ES (1) ES2545769T3 (ru)
HR (1) HRP20150773T1 (ru)
HU (1) HUE025134T2 (ru)
IL (2) IL186486A0 (ru)
ME (1) ME02191B (ru)
MX (1) MX2007012569A (ru)
NO (1) NO344249B1 (ru)
NZ (1) NZ562093A (ru)
PL (1) PL1874819T3 (ru)
PT (1) PT1874819E (ru)
RS (1) RS54127B1 (ru)
RU (2) RU2458071C2 (ru)
SG (1) SG161292A1 (ru)
SI (1) SI1874819T1 (ru)
UA (1) UA94403C2 (ru)
WO (1) WO2006111353A2 (ru)
ZA (1) ZA200708201B (ru)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006237159B2 (en) * 2005-04-18 2011-03-24 Amgen Research (Munich) Gmbh Antibody neutralizers of human granulocyte macrophage colony stimulating factor
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
CN101501070B (zh) * 2006-02-08 2013-12-25 诺福泰克公司 抗原性gm-csf肽和针对gm-csf的抗体
US20080171038A1 (en) * 2006-11-08 2008-07-17 Kalobios Pharmaceuticals, Inc. Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
US8398972B2 (en) 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
WO2008097510A1 (en) * 2007-02-08 2008-08-14 Merck & Co., Inc. Antibodies specific for dkk-1
EP2160407A4 (en) * 2007-05-23 2011-07-27 Crc For Asthma And Airways Ltd NEUTRALIZING ANTIBODIES
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
DK2215119T3 (da) * 2007-11-13 2013-02-04 Evec Inc Monoklonale antistoffer der binder til HGM-CSF og medicinske sammensætninger omfattende de samme.
JP4954326B2 (ja) * 2008-04-11 2012-06-13 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
KR101824512B1 (ko) 2008-04-28 2018-02-02 휴머니건, 아이엔씨. 과립구-대식세포 콜로니 자극 인자에 대한 항체
EA024654B1 (ru) * 2008-04-29 2016-10-31 Эмджен Рисерч (Мьюник) Гмбх Ингибиторы гранулоцитарно-макрофагального колониестимулирующего фактора (gm-csf) и интерлейкина-17 (il-17) для терапии
RU2366422C1 (ru) * 2008-05-19 2009-09-10 Государственное учреждение Научно-исследовательский институт фармакологии Томского научного центра Сибирского отделения Российской Академии медицинских наук (ГУ НИИ фармакологии ТНЦ СО РАМН) Способ коррекции депрессии гранулоцитопоэза при цитостатическом воздействии
ES2978209T3 (es) 2008-12-22 2024-09-09 Univ Melbourne Tratamiento del dolor
RU2712273C2 (ru) * 2008-12-22 2020-01-28 Де Юниверсити Оф Мельбурн Лечение остеоартрита
CN102439039A (zh) * 2009-05-05 2012-05-02 莫佛塞斯公司 多发性硬化的治疗
CA2827923C (en) 2011-02-25 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc antibody
AU2012280267B2 (en) 2011-07-06 2016-04-21 Morphosys Ag Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof
WO2013090989A1 (en) * 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
US9833410B2 (en) * 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
AR093297A1 (es) * 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
US20160024200A1 (en) * 2013-03-14 2016-01-28 John Schrader Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof
WO2015028666A1 (en) * 2013-08-30 2015-03-05 Takeda Gmbh Neutralizing antibody or a fragment thereof specifically binding primate gm-csf for use in the treatment and/or prevention of psoriasis
AU2014314053C1 (en) * 2013-08-30 2023-11-02 Takeda Pharmaceutical Company Limited Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
JP6502931B2 (ja) 2013-10-11 2019-04-17 アメリカ合衆国 Ｔｅｍ８抗体およびその使用
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
EP3139960B1 (en) * 2014-05-07 2024-01-17 Takeda Pharmaceutical Company Limited Liquid formulation comprising gm-csf neutralizing compound
WO2016077789A1 (en) 2014-11-14 2016-05-19 The Usa, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
WO2016079276A1 (en) * 2014-11-21 2016-05-26 Takeda Gmbh Use of an anti-gm-csf antagonist and an anti-ccr2 antagonist in the treatment of an infectious disease
WO2016079277A1 (en) * 2014-11-21 2016-05-26 Takeda Gmbh Use of an anti-gm-csf antagonist in the treatment of an infectious disease
US10301377B2 (en) 2015-02-24 2019-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
GB201503139D0 (en) * 2015-02-25 2015-04-08 Univ Leicester Diagnostic and therapeutic target
US10562960B2 (en) 2015-03-20 2020-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to gp120 and their use
CA2997809A1 (en) 2015-10-07 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
EP3371214A1 (en) 2015-11-03 2018-09-12 THE UNITED STATES OF AMERICA, represented by the S Neutralizing antibodies to hiv-1 gp41 and their use
WO2017192589A1 (en) 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
CN106872428A (zh) * 2017-02-07 2017-06-20 远见生物科技（上海）有限公司 一种用于检测中性粒细胞呼吸爆发功能的试剂盒
EP3580235B1 (en) 2017-02-10 2024-05-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
SG11202003096UA (en) 2017-10-02 2020-05-28 Humanigen Inc Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
JP7138896B2 (ja) 2017-10-24 2022-09-20 株式会社Asm 低包接率ポリロタキサンの製造方法
US11976109B2 (en) 2018-01-02 2024-05-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
US11760790B2 (en) 2018-02-21 2023-09-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 Env and their use
JP7603580B2 (ja) * 2018-10-15 2024-12-20 エリクシロン・イミュノセラピューティクス・（ホンコン）・リミテッド 顆粒球マクロファージコロニー刺激因子に対する抗体及びそれらの使用
US11078264B2 (en) 2018-10-17 2021-08-03 University Of Connecticut Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth
EP3883609A2 (en) 2018-12-20 2021-09-29 The United States of America, as represented by the Secretary, Department of Health and Human Services Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
WO2020227228A2 (en) 2019-05-03 2020-11-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
US20230085439A1 (en) 2019-05-21 2023-03-16 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use
KR20220031054A (ko) 2019-07-02 2022-03-11 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Egfrviii에 결합하는 단일클론 항체 및 이의 용도
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
WO2022132904A1 (en) 2020-12-17 2022-06-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies targeting sars-cov-2
WO2022173689A1 (en) 2021-02-09 2022-08-18 University Of Georgia Research Foundation, Inc. Human monoclonal antibodies against pneumococcal antigens
US20240117011A1 (en) 2021-02-09 2024-04-11 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Antibodies targeting the spike protein of coronaviruses
AU2022345251A1 (en) 2021-09-17 2024-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
CN118984836A (zh) 2022-02-10 2024-11-19 美国政府(由卫生和人类服务部的部长所代表) 广泛靶向冠状病毒的人单克隆抗体
US20250197483A1 (en) 2022-03-28 2025-06-19 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 env and their use
WO2024030829A1 (en) 2022-08-01 2024-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
WO2024054822A1 (en) 2022-09-07 2024-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered sars-cov-2 antibodies with increased neutralization breadth
WO2024064826A1 (en) 2022-09-22 2024-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
WO2024137381A1 (en) 2022-12-19 2024-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies for treating sars-cov-2 infection
WO2024138151A1 (en) 2022-12-22 2024-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ebolavirus (sudan and zaire) antibodies from non-human primates and human vaccinees
WO2024243355A1 (en) 2023-05-24 2024-11-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that target the rh5 complex of blood-stage plasmodium falciparum
WO2025014896A1 (en) 2023-07-07 2025-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Humanized 40h3 antibody
WO2025024233A1 (en) 2023-07-21 2025-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bispecific antibodies that broadly target coronaviruses
WO2025106427A1 (en) 2023-11-14 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
WO2025117384A1 (en) 2023-12-01 2025-06-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing influenza hemagglutinin stem-directed antibodies
WO2025137284A2 (en) 2023-12-21 2025-06-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing antibodies against sars-cov-2 and sars-cov variants

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8624899D0 (en) * 1986-10-17 1986-11-19 Sandoz Ltd Monoclonal antibodies
US5070013A (en) * 1988-05-31 1991-12-03 Schering Corporation Immunochemical assay for human granulocyte-macrophage colony stimulating factor
CA2060741A1 (en) * 1991-02-11 1992-08-12 Robert S. Greenfield Gm-csf inhibiting oligopeptides
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
ATE321849T1 (de) 1997-04-23 2006-04-15 Univ Zuerich Verfahren zur erkennung von nucleinsäuremolekülen codierend für (poly)peptide, welche mit zielmolekülen interagieren
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
AU761587B2 (en) 1998-04-21 2003-06-05 Amgen Research (Munich) Gmbh CD19xCD3 specific polypeptides and uses thereof
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
BR0108499A (pt) 2000-02-14 2003-03-11 Mitsubishi Pharma Corp Agente terapêutico para hepatite c
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2003217386B2 (en) 2002-02-13 2008-06-26 Ludwig Institute For Cancer Research Humanized GM-CSF antibodies
DK1593690T3 (da) * 2004-05-05 2009-11-09 Micromet Ag Fremstilling af ScFv-antistoffragmenter
AU2006237159B2 (en) * 2005-04-18 2011-03-24 Amgen Research (Munich) Gmbh Antibody neutralizers of human granulocyte macrophage colony stimulating factor
PT3620171T (pt) 2005-05-18 2022-06-30 Morphosys Ag Anticorpos anti-gm-csf e suas utilizações
CN101501070B (zh) 2006-02-08 2013-12-25 诺福泰克公司 抗原性gm-csf肽和针对gm-csf的抗体

Also Published As

Publication number Publication date
BRPI0608281B1 (pt) 2020-01-28
KR101704809B1 (ko) 2017-02-08
RS54127B1 (en) 2015-12-31
ES2545769T3 (es) 2015-09-15
ZA200708201B (en) 2008-07-30
CN103342751A (zh) 2013-10-09
IL220412A0 (en) 2012-07-31
IL186486A0 (en) 2008-01-20
JP5085533B2 (ja) 2012-11-28
US20090297532A1 (en) 2009-12-03
ME02191B (me) 2016-02-20
RU2012115683A (ru) 2013-10-27
CA2605402C (en) 2017-05-23
US20120009195A1 (en) 2012-01-12
PL1874819T3 (pl) 2015-10-30
EP2468774A3 (en) 2013-01-02
US10138297B2 (en) 2018-11-27
WO2006111353A2 (en) 2006-10-26
HK1112003A1 (en) 2008-08-22
PT1874819E (pt) 2015-09-17
US9067993B2 (en) 2015-06-30
EP1874819B1 (en) 2015-05-27
EP2468774A2 (en) 2012-06-27
SI1874819T1 (sl) 2015-09-30
US8017748B2 (en) 2011-09-13
EP1874819A2 (en) 2008-01-09
EA013162B1 (ru) 2010-02-26
MX2007012569A (es) 2007-12-06
IL220412A (en) 2017-04-30
AU2006237159B2 (en) 2011-03-24
HRP20150773T1 (hr) 2015-08-28
SG161292A1 (en) 2010-05-27
NO344249B1 (no) 2019-10-21
NO20075802L (no) 2008-01-10
JP2008536505A (ja) 2008-09-11
EA200702008A1 (ru) 2008-06-30
UA94403C2 (ru) 2011-05-10
RU2458071C2 (ru) 2012-08-10
BRPI0608281B8 (pt) 2021-05-25
KR20080005962A (ko) 2008-01-15
RU2007138341A (ru) 2009-05-27
EA017420B1 (ru) 2012-12-28
DK1874819T3 (en) 2015-08-31
US20160130338A1 (en) 2016-05-12
HUE025134T2 (en) 2016-01-28
CA2605402A1 (en) 2006-10-26
CN101184777B (zh) 2013-07-17
EA017420B9 (ru) 2013-03-29
CN103342751B (zh) 2015-12-23
AU2006237159A1 (en) 2006-10-26
CY1116632T1 (el) 2017-03-15
KR20150091193A (ko) 2015-08-07
WO2006111353A3 (en) 2007-04-19
NZ562093A (en) 2011-01-28
HK1190161A1 (zh) 2014-06-27
CN101184777A (zh) 2008-05-21
BRPI0608281A2 (pt) 2009-12-15

Similar Documents

Publication Publication Date Title
EA200901500A1 (ru) Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека
EA201070695A1 (ru) Молекулы гуманизированных антител, специфичных к il-31
DE602006013029D1 (de) Anti-egfr-antikörper
CY2018027I2 (el) Ανταγωνιστικα αντισωματα il-17
IL244803B (en) Human anti-beta antibodies and their use
CY1113224T1 (el) Νεο αντισωμα αντι-ρlgf
TW200626171A (en) Fixed dosing of HER antibodies
DK3421498T3 (da) Monoklonale antistoffer mod claudin-18 til behandling af cancer
TW200639182A (en) Antibody variants and uses thereof
EA200800812A1 (ru) Композиции антитела против cd3
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
EA200900492A1 (ru) Молекулы антител, которые связываются с il-17a и il-17f
EA200870050A1 (ru) Анти-il-17-антитела
EA201100694A1 (ru) Антитело к cd38 человека и его применение
EA200802182A1 (ru) Модифицированные гуманизированные антитела против интерлейкина-18
TW200745161A (en) Stable antibody formulation
WO2009135861A3 (en) Humanized antibodies against human interferon-alpha
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
ITRM20040105A1 (it) Anticorpo monoclonale antitenascina umana.
UA98100C2 (ru) Гуманизированное моноклональное антитело, которое связывается с человеческим nogo и нейтрализует его
FI20020807A0 (fi) Uusia humanisoituja anti-VAP-1 monoklonaalisia vasta-aineita
UA96426C2 (ru) Выделенное человеческое или гуманизированное антитело, которое специфически связывается с il-13
IL172548A0 (en) Emitter-binding peptides causing a change in the spectral emission properties of the emitter
EA202190387A1 (ru) Антитело к cd38 человека и его применение

Legal Events

Date Code Title Description
PD1A Registration of transfer to a eurasian application by order of succession in title
TH4A Publication of the corrected specification to eurasian patent
TC4A Change in name of a patent proprietor in a eurasian patent